Literature DB >> 19319478

Involvement of mitogen-activated protein kinases and nuclear factor kappa B pathways in signaling COX-2 expression in chronic rhinosinusitis.

Zhenlin Wang1, Qiuhang Zhang, Yuan Li, Peng Li, Gehua Zhang, Yulu Li.   

Abstract

OBJECTIVE: To investigate the signal pathways involved in cyclooxygenase-2 (COX-2) expression in chronic rhinosinusitis (CRS).
METHODS: The expressions of COX-2, p38 mitogen-activated protein kinase (p38MAPK), extracellular signal-regulated kinase (ERK), and nuclear factor kappa B (NF-kappaB) in nasal mucosa were detected by immunohistological stain and polymerase chain reaction (PCR). Their expressions and prostaglandin E2 (PGE(2)) release were determined by PCR, Western blot and enzyme immunoassay (EIA) in human nasal epithelia (HNE) cells after lipopolysaccharide (LPS) induction, and/or small interfering RNA (siRNA) transfection.
RESULTS: Positive protein expressions of COX-2, p38MAPK, ERK, NF-kappaB subunits were detected in epithelial and inflammatory cells. Their mRNA levels were significantly higher in CRS than controls (P < 0.05). The expressions varied in time and concentration-dependent manner in LPS-induced HNE cells. COX-2 expression was suppressed by siRNAs of P38MAPK, ERK, and NF-kappaB; however, COX-2-specific siRNA had no blocking effect on them. SiRNAs of P38MAPK or ERK could block NF-kappaB, but NF-kappaB-specific siRNA had no blocking effect on the former. SiRNA of p38MAPK, or ERK did not inhibit each other.
CONCLUSION: Upregulation of COX-2 expression suggested its role as a mediator in CRS. ERK and p38MAPK pathways were involved in signaling COX-2 through NF-kappaB pathway.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19319478     DOI: 10.1007/s00011-009-0030-x

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  32 in total

1.  Expression of cyclooxygenase and lipoxygenase enzymes in nasal polyps of aspirin-sensitive and aspirin-tolerant patients.

Authors:  Jonathan M Owens; Kenneth R Shroyer; Todd T Kingdom
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2006-06

2.  Signaling pathways regulating IL-1alpha-induced COX-2 expression.

Authors:  S Ogata; Y Kubota; T Yamashiro; H Takeuchi; T Ninomiya; Y Suyama; K Shirasuna
Journal:  J Dent Res       Date:  2007-02       Impact factor: 6.116

3.  Differential modulation of COX-2 expression in A549 airway epithelial cells by structurally distinct PPAR(gamma) agonists: evidence for disparate functional effects which are independent of NF-(kappa)B and PPAR(gamma).

Authors:  Kajal M Patel; Karen L Wright; Paul Whittaker; Probir Chakravarty; Malcolm L Watson; Stephen G Ward
Journal:  Cell Signal       Date:  2005-01-07       Impact factor: 4.315

4.  Lysophosphatidic acid-induced transactivation of epidermal growth factor receptor regulates cyclo-oxygenase-2 expression and prostaglandin E(2) release via C/EBPbeta in human bronchial epithelial cells.

Authors:  Donghong He; Viswanathan Natarajan; Randi Stern; Irina A Gorshkova; Julian Solway; Ernst Wm Spannhake; Yutong Zhao
Journal:  Biochem J       Date:  2008-05-15       Impact factor: 3.857

Review 5.  Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.

Authors:  Kyung-Soo Chun; Young-Joon Surh
Journal:  Biochem Pharmacol       Date:  2004-09-15       Impact factor: 5.858

6.  Cyclooxygenase-2/prostaglandin D2/CRTH2 pathway mediates double-stranded RNA-induced enhancement of allergic airway inflammation.

Authors:  Yoshiki Shiraishi; Koichiro Asano; Kyoko Niimi; Koichi Fukunaga; Misa Wakaki; Junko Kagyo; Takahisa Takihara; Soichiro Ueda; Takeshi Nakajima; Tsuyoshi Oguma; Yusuke Suzuki; Tetsuya Shiomi; Koichi Sayama; Shizuko Kagawa; Eiji Ikeda; Hiroyuki Hirai; Kinya Nagata; Masataka Nakamura; Taku Miyasho; Akitoshi Ishizaka
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

7.  Increased prostaglandin E2 levels in the airway of patients with eosinophilic bronchitis.

Authors:  B Sastre; M Fernández-Nieto; R Mollá; E López; C Lahoz; J Sastre; V del Pozo; S Quirce
Journal:  Allergy       Date:  2007-10-24       Impact factor: 13.146

8.  COX-2 expression and inflammatory effects by diesel exhaust particles in vitro and in vivo.

Authors:  Eun-Kyung Ahn; Hyoung-Kyu Yoon; Bo Keun Jee; Hye-Jin Ko; Kweon-Haeng Lee; Hyung Jung Kim; Young Lim
Journal:  Toxicol Lett       Date:  2007-12-04       Impact factor: 4.372

Review 9.  Cyclooxygenases and the pathogenesis of chronic rhinosinusitis and nasal polyposis.

Authors:  Josep M Guilemany; Jordi Roca-Ferrer; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2008-05       Impact factor: 4.919

10.  Nontypeable Haemophilus influenzae induces COX-2 and PGE2 expression in lung epithelial cells via activation of p38 MAPK and NF-kappa B.

Authors:  Feng Xu; Zhihao Xu; Rong Zhang; Zuqun Wu; Jae-Hyang Lim; Tomoaki Koga; Jian-Dong Li; Huahao Shen
Journal:  Respir Res       Date:  2008-01-31
View more
  4 in total

Review 1.  Pathways analysis of molecular markers in chronic sinusitis with polyps.

Authors:  Michael P Platt; Zachary Soler; Ralph Metson; Konstantina M Stankovic
Journal:  Otolaryngol Head Neck Surg       Date:  2011-05       Impact factor: 3.497

2.  Protection of LPS-induced murine acute lung injury by sphingosine-1-phosphate lyase suppression.

Authors:  Yutong Zhao; Irina A Gorshkova; Evgeny Berdyshev; Donghong He; Panfeng Fu; Wenli Ma; Yanlin Su; Peter V Usatyuk; Srikanth Pendyala; Babak Oskouian; Julie D Saba; Joe G N Garcia; Viswanathan Natarajan
Journal:  Am J Respir Cell Mol Biol       Date:  2010-12-10       Impact factor: 6.914

3.  Anthraquinone G503 induces apoptosis in gastric cancer cells through the mitochondrial pathway.

Authors:  Lijun Huang; Ting Zhang; Shuai Li; Junting Duan; Fang Ye; Hanxiang Li; Zhigang She; Guoquan Gao; Xia Yang
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

Review 4.  Allergic Aspergillus Rhinosinusitis.

Authors:  Arunaloke Chakrabarti; Harsimran Kaur
Journal:  J Fungi (Basel)       Date:  2016-12-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.